List view / Grid view
13 July 2015 | By Victoria White
In the Phase II IMvigor 210 study, Roche’s atezolizumab shrank tumours in people with locally advanced or metastatic urothelial bladder cancer (UBC)...
10 July 2015 | By Victoria White
Janssen-Cilag International announced today that the European Commission (EC) has approved Imbruvica® (ibrutinib) capsules as a treatment option for adult patients with Waldenström’s macroglobulinemia (WM).
9 July 2015 | By Victoria White
Around half of all breast cancer patients could one day benefit from having the cheap and widely-available hormone progesterone added to their treatment...
17 June 2015 | By
Lilly and SCRI have entered a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor...
17 June 2015 | By Victoria White
OncoSec has enrolled the first patient into a Phase II clinical trial of ImmunoPulse IL-12 in patients with squamous cell carcinoma of the head and neck...
12 June 2015 | By Victoria White
ORYX's Phase I/IIa trial assessing oncolytic parvovirus H1 as a treatment for patients with glioblastoma multiforme has been successfully completed...
11 June 2015 | By Victoria White
The first patient in Singapore has been treated with TheraSphere radioembolization therapy- a treatment for primary liver cancer and metastatic bowel cancer...
10 June 2015 | By kdm communications
Quotient Clinical, the Translational Pharmaceutics® Company, has announced the successful completion of an Enabled-First-in-Human® (Enabled-FIH) program for US biotech company Corcept Therapeutics Incorporated...
4 June 2015 | By Victoria White
Exalenz Bioscience has initiated a clinical study designed to investigate its BreathID test to non-invasively detect primary liver cancer...
4 June 2015 | By Victoria White
AVEO has received confirmation of support from two CHMP members following pre-submission meetings to discuss the potential submission of a MAA for tivozanib...
3 June 2015 | By Victoria White
Janssen Research & Development has announced data from a Phase 3 study of trabectedin (YONDELIS) in patients with two common types of soft tissue sarcoma...
1 June 2015 | By Victoria White
Results from a study of idelalisib in combination with ofatumumab in previously-treated patients with chronic lymphocytic leukaemia have been announced...
26 May 2015 | By Victoria White
A genetically engineered herpes virus, T-VEC, can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action...
18 May 2015 | By Victoria White
The first patient has been dosed in the Phase 2 clinical trial of tipifarnib in patients with locally advanced tumours that carry HRAS mutations...
11 May 2015 | By Victoria White
Roche has announced that data from 10 of its approved cancer medicines and 10 of its investigational medicines will be presented at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2015).
